750 Shares in Catalent, Inc. (NYSE:CTLT) Bought by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent, Inc. (NYSE:CTLT) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 750 shares of the company’s stock, valued at approximately $42,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Lindbrook Capital LLC lifted its position in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares during the last quarter. GAMMA Investing LLC bought a new stake in shares of Catalent during the 4th quarter worth $33,000. Rakuten Securities Inc. bought a new stake in shares of Catalent during the 4th quarter worth $46,000. Federated Hermes Inc. bought a new stake in shares of Catalent during the 4th quarter worth $46,000. Finally, Mather Group LLC. bought a new stake in shares of Catalent during the 1st quarter worth $52,000.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CTLT shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Barclays increased their price target on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Finally, StockNews.com started coverage on Catalent in a research note on Thursday, August 1st. They set a “sell” rating for the company. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $55.65.

Insiders Place Their Bets

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders sold a total of 14,810 shares of company stock valued at $858,941 over the last 90 days. Insiders own 0.31% of the company’s stock.

Catalent Stock Performance

Shares of NYSE CTLT traded up $0.41 during mid-day trading on Tuesday, hitting $59.56. The company had a trading volume of 1,590,661 shares, compared to its average volume of 2,218,511. The company has a market capitalization of $10.78 billion, a price-to-earnings ratio of -9.69, a P/E/G ratio of 2.47 and a beta of 1.16. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $60.20. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The stock’s 50-day moving average price is $56.66 and its 200-day moving average price is $56.12.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. On average, sell-side analysts forecast that Catalent, Inc. will post -0.17 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.